Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study
Neuropsychopharmacology Reports · 2026
DOI: 10.1002/npr2.70171 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2026. Verfasst von Wataru Omori und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Healthy Aging, Receptors, Nerve Growth Factor, Depression. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Themen: Depression, Demenz
Abstract (Originalsprache)
Objective
The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom and cognitive associations.
Methods
CSF p75NTR‐ECD was measured in 50 participants (HC, n = 19; LLD, n = 19; AD, n = 12). The primary linear model adjusted for age, sex, and body mass index. Exploratory symptom and cognitive models additionally adjusted for diagnostic group; six p values underwent Benjamini–Hochberg false discovery rate (FDR) correction. Plate and below‐calibrator sensitivity analyses were performed.
Results
CSF p75NTR‐ECD was higher in HC than in AD (B = 131.2 pg/mL, 95% CI 42.8–219.6, p = 0.005) and higher in LLD than in AD (B = 154.6 pg/mL, 95% CI 68.9–240.3, p < 0.001); HC and LLD did not differ. No symptom or cognitive association remained significant after diagnostic‐group adjustment and FDR correction (all q ≥ 0.117). Plate adjustment did not materially change the primary contrasts. Excluding three concentrations below the lowest calibrator preserved the LLD–AD contrast but attenuated the HC–AD contrast.
Conclusions
CSF p75NTR‐ECD showed preliminary differences across clinically defined groups. Because the sample was small, the recruitment site was perfectly confounded with AD versus non‐AD status, and diagnoses were not uniformly biomarker‐confirmed, the findings do not establish causality, clinical diagnostic utility, or added value beyond established AD biomarkers and require independent multisite replication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan.
- Division of Psychiatry and Neuroscience, Institute for Clinical Research, NHO Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan.
- Department of Psychiatry and Neuroscience, Center for Metabolic Regulation of Healthy Aging, Faculty of Life Science, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Wataru Omori, Naoto Kajitani, Mami Okada-Tsuchioka, Minoru Takebayashi
Förderung
- JSPS KAKENHI
Zitieren
APA
Omori, W., Kajitani, N., Okada-Tsuchioka, M., & Takebayashi, M. (2026). Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70171
Vancouver
Omori W, Kajitani N, Okada-Tsuchioka M, Takebayashi M. Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study. Neuropsychopharmacology Reports. 2026. doi:10.1002/npr2.70171
BibTeX
@article{Omori2026,
author = {Omori, Wataru and Kajitani, Naoto and Okada-Tsuchioka, Mami and Takebayashi, Minoru},
title = {Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study},
journal = {Neuropsychopharmacology Reports},
year = {2026},
doi = {10.1002/npr2.70171}
}
EUVIMED